IL-NIELSENIQ/FOXINTEL
8.12.2021 13:03:07 CET | Business Wire | Press release
The shopper journey continually evolves as consumers have more control over what they do, see, and hear. That means the tools used to measure and analyze sales, market share and consumer behavior must also change. In an environment that continues to experience seismic shifts, measuring when, where and how consumers are buying is imperative. This allows fast-moving consumer goods (FMCG) manufacturers and retailers to anticipate trends and react faster to consumers’ needs and expectations.
Although the fastest growing channel in Western Europe and North America is online, e-commerce measurement tools are largely fragmented. Users must combine data from multiple sources to get a full picture of the market. NielsenIQ is transforming the FMCG and retail industry with its innovative solutions and precise insights, which offer an integrated, accurate, complete, and more granular view of the offline and online marketplace—making it easier to analyze trends across channels.
Our latest acquisition, Foxintelligence, will strengthen our offering globally.
Foxintelligence is the largest e-commerce measurement and consumer data analytics company in Europe. It operates Europe’s largest GDPR-compliant consumer panel, boasting over 600,000 active online buyers in France, Germany, Italy, Spain, and the United Kingdom and will be able to expand its coverage and offering to additional markets as a NielsenIQ-powered company.
Eight months after becoming a standalone company, NielsenIQ has made several key acquisitions and significantly increased its investments to accelerate its product delivery and build comprehensive solutions, transforming the measurement and analytics solutions available to the rapidly changing FMCG and retail industry.
“Our goal is to transform the way we operate and serve our customers, helping them to accelerate growth. The investments we have made so far are building the foundation for NielsenIQ's transformation and bringing key talent in-house to address some of the most critical issues our customers face today and will face in the future,” said Lorena Elizondo, Chief Strategy Officer, NielsenIQ.
“NielsenIQ’s ambition is to approach e-commerce holistically. Foxintelligence is instrumental in this strategy, expanding the footprint of our unmatched retail measurement solution. They uncover the online blind spots like marketplaces, category specialists, direct-to-consumer, quick-commerce and last milers, among others, providing full-market coverage,” said Clément Colin, Head of International E-commerce Measurement, NielsenIQ.
Foxintelligence gathers and anonymizes e-receipts to create detailed, comprehensive, and proprietary transaction data. This data is the cornerstone of market intelligence in today’s digital consumption age, and NielsenIQ will propel it forward.
“We are extremely proud and happy to join the NielsenIQ family. We have been working for over a year on common themes to bring ever more value to our clients and we will now provide them a more comprehensive and integrated vision of the online and offline marketplace,” said Edouard Nattée, CEO and Founder of Foxintelligence.
The acquisition of Foxintelligence marks the latest bold step NielsenIQ is taking in providing groundbreaking, comprehensive e-commerce data. In September 2021, NielsenIQ acquired Rakuten Intelligence and Data Impact to enhance its e-commerce solution portfolio and scale it globally.
About NielsenIQ
NielsenIQ is the leader in providing the most complete, unbiased view of consumer behavior, globally. Powered by a groundbreaking consumer data platform and fueled by rich analytic capabilities, NielsenIQ enables bold, confident decision-making for the world’s leading consumer goods companies and retailers.
Using comprehensive data sets and measuring all transactions equally, NielsenIQ gives clients a forward-looking view into consumer behavior in order to optimize performance across all retail platforms. Our open philosophy on data integration enables the most influential consumer data sets on the planet. NielsenIQ delivers the complete truth.
NielsenIQ, an Advent International portfolio company, has operations in nearly 100 markets, covering more than 90% of the world’s population. For more information, visit NielsenIQ.com .
About Foxintelligence
Foxintelligence mission is to empower decision-makers with data to improve the way societies and companies work. The company delivers the best insights on the latest European ecommerce trends, by unlocking intelligence from hundreds of merchants and thousands of brands e-receipts. By doing so, Foxintelligence collects commercial information about ecommerce from e-mails (e.g., e-receipts): thanks to their proprietary technology, Foxintelligence can structure this vast amount of data to generate unseen insights on the market and make them available on their SaaS platform: Foxapp.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005244/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom